Sector News

Deal-talkers J&J, Actelion reportedly land on a price, but spinoff details still pending

January 13, 2017
Life sciences

Johnson & Johnson and Actelion are working out a deal that would send the Swiss biotech’s marketed meds to New Jersey.

Johnson & Johnson and Actelion may have finally settled a key condition of their long-discussed transaction.

The pair has landed on a price for the deal, Bloomberg reports, although sources didn’t tell the news service what that price was. Reuters reported earlier this month that J&J was considering a price in the $260-per-share range for Actelion’s marketed meds, a figure that would bring the buy to more than $28 billion.

Now, word has it the companies are hammering out valuations for Actelion’s R&D assets, which would reportedly be spun off into a new company as part of any acquisition. Which products specifically would go into that unit and how much ownership Actelion’s investors would keep are both under negotiation, but sources say the companies could strike a pact as early as this month.

J&J’s courtship of the Swiss biotech has been a long one, in part thanks to Actelion founder and CEO Jean-Paul Clozel’s desire to keep a piece of his company flying solo. Earlier talks hit a snag in December when the pair quit talking—only to restart a week later and force Sanofi, which had entered after J&J threw in the towel, out of the picture.

New Jersey-based J&J, which is seeking revenue growth now that a biosimilar competitor to top med Remicade has arrived in the U.S., has been more or less amenable to Clozel’s desires, though working out the complex deal structure has been slow going.

By Carly Helfand

Source: Fierce Pharma

comments closed

Related News

May 21, 2022

As monkeypox cases emerge in US and Europe, Bavarian Nordic inks vaccine order

Life sciences

A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.

May 21, 2022

Moderna chairman Afeyan defends hiring practices after CFO debacle: report

Life sciences

Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.

May 21, 2022

Merck to pay up to $1.4B in cancer deal with Kelun, but details are scarce

Life sciences

Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”